4//SEC Filing
Hunter Laura B. 4
Accession 0001140361-13-017687
CIK 0001375247other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 2:35 PM ET
Size
14.4 KB
Accession
0001140361-13-017687
Insider Transaction Report
Form 4
Hunter Laura B.
VP, Gen Counsel & Secretary
Transactions
- Disposition to Issuer
Stock option (right to buy)
2013-04-25$14.55/sh−40,000$582,000→ 0 totalExercise: $9.45Exp: 2018-09-03→ Common stock (40,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2013-04-25$12.51/sh−25,000$312,750→ 0 totalExercise: $11.49Exp: 2020-03-08→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2013-04-25$11.30/sh−25,000$282,500→ 0 totalExercise: $12.70Exp: 2022-05-01→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2013-04-25$18.14/sh−15,000$272,100→ 0 totalExercise: $5.86Exp: 2019-03-03→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock option (right to buy)
2013-04-25$14.29/sh−25,000$357,250→ 0 totalExercise: $9.71Exp: 2021-11-29→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]This stock option immediately vested in full and was converted into the right to receive cash in an amount equal to the product of (A) the total number of shares subject to the option, and (B) the difference between $24.00 minus the exercise price per share of the option, pursuant to the terms of the Agreement and Plan of Merger, dated March 19, 2013, among the issuer, Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals, International, Inc., as amended, and the issuer's 2005 Stock Incentive Plan, as amended, and as approved by the issuer's Compensation Committee.
Documents
Issuer
Obagi Medical Products, Inc.
CIK 0001375247
Entity typeother
Related Parties
1- filerCIK 0001449951
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 2:35 PM ET
- Size
- 14.4 KB